![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/31/2891477/0/en/Lipella-Pharmaceuticals-Announces-Completion-of-Site-Initiation-Visit-for-Phase-2a-Trial-of-LP-310-in-Oral-Lichen-Planus.html
https://www.globenewswire.com/news-release/2024/05/29/2889786/0/en/Lipella-Pharmaceuticals-Announces-Abstract-Publication-at-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/21/2885517/0/en/Following-Guidance-from-U-S-Food-Drug-Administration-in-Type-C-Meeting-Lipella-Pharmaceuticals-to-Advance-Lead-Product-Candidate-to-Phase-2b.html
https://www.globenewswire.com/news-release/2024/04/17/2864435/0/en/Lipella-Pharmaceuticals-Expands-its-Advisory-Board-to-Include-Oncology-Expertise.html
https://www.globenewswire.com/news-release/2024/04/05/2858476/0/en/Lipella-Pharmaceuticals-to-Publish-Abstract-Detailing-Compelling-Preclinical-Support-for-New-Product-Candidate-at-ASCO-2024.html
https://www.globenewswire.com/news-release/2024/04/03/2856846/0/en/Lipella-Pharmaceuticals-Announces-FDA-Type-C-Meeting-for-LP-10-for-Hemorrhagic-Cystitis.html
https://www.globenewswire.com//news-release/2024/03/05/2840362/0/en/Lipella-Pharmaceuticals-Announces-FDA-Clearance-of-IND-for-LP-410-for-Oral-Graft-Versus-Host-Disease-Advancing-Clinical-Pipeline.html
https://www.globenewswire.com//news-release/2024/02/20/2831817/0/en/Lipella-Pharmaceuticals-to-Present-at-PropThink-Digital-Investor-Conference.html
https://www.globenewswire.com//news-release/2023/12/20/2799209/0/en/Lipella-Pharmaceuticals-Marks-Successful-First-Year-with-Strategic-Progress-and-Key-Milestones-Accomplished.html
https://www.prnewswire.com/news-releases/fda-grants-orphan-designation-for-lipellas-lp-310-drug-candidate-for-oral-graft-versus-host-disease-301984199.html